Medplus Health Services Q4 FY26 Revenue Jumps 23.5% YoY to ₹18,644m
MedPlus Health Services reported Q4 FY2026 revenue of ₹18,644 million, up 23.5% YoY. Gross Margin was ₹4,934 million (26.5%). The company added 147 net stores in Q4, reaching 5,330 total. Pharmacy Operating EBITDA was ₹1,022 million. For FY2026, revenue grew 12.3% to ₹68,925 million.
The announcement details solid financial performance with significant revenue growth and store expansion. This indicates positive business momentum, impacting investor confidence and potentially the stock price.
The company reported strong year-on-year revenue growth of 23.5% and sequential growth in revenue and EBITDA. The increase in store count and healthy operating cash flow further contribute to the positive sentiment.
MedPlus Health Services Limited has announced its audited financial results for the quarter and financial year ended March 31, 2026. The company reported a revenue of ₹18,644 million for Q4 FY2026, marking a significant year-on-year increase of 23.5% or ₹3,548 million. Sequentially, revenue grew by 3.2% or ₹583 million from Q3 FY2026.
The Gross Margin for Q4 FY2026 stood at ₹4,934 million, with a Gross Margin percentage of 26.5%. This represents a decrease of 10 basis points year-on-year but an increase of 30 basis points quarter-on-quarter.
During the quarter, MedPlus added 218 stores, with 295 gross additions and 77 closures, resulting in a net addition of 147 stores beyond Tier-One locations. The company's total store count reached 5,330 as of March 31, 2026.
Pharmacy Operating EBITDA was ₹1,022 million, with an Operating EBITDA margin of 5.6%, an increase of 40 basis points quarter-on-quarter. The consolidated Company Operating EBITDA was ₹1,076 million. Operating Cash Flow was ₹917 million, representing 85.2% of Operating EBITDA, and the company maintained a closing cash and bank balance of ₹5,942 million.
For the full financial year 2026, revenue stood at ₹68,925 million, an increase of 12.3% over FY2025. Gross Margin was ₹18,079 million (26.2% GM%), and Pharmacy Operating EBITDA was ₹3,476 million (5.1% margin). The company added 618 stores net in FY2026, with 792 gross additions.
What to do with a filing like this
Medplus Health Services Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Medplus Health Services Limited. Read the original for the full detail.